Adjunctive Cilostazol to Dual Antiplatelet Therapy to Enhance Mobilization of Endothelial Progenitor Cell in Patients with Acute Myocardial Infarction: A Randomized, Placebo-Controlled EPISODE Trial.
Yongwhi ParkJin Hyun KimTae Ho KimJin-Sin KohSeok-Jae HwangJin-Yong HwangYoung Hoon JeongPublished in: Journal of clinical medicine (2020)
Adjunctive cilostazol on top of clopidogrel and aspirin versus DAPT alone is associated with increased EPC mobilization and decreased platelet reactivity in AMI patients, suggesting its pleiotropic effects against atherothrombotic events (NCT04407312).
Keyphrases
- antiplatelet therapy
- percutaneous coronary intervention
- acute myocardial infarction
- acute coronary syndrome
- end stage renal disease
- coronary artery disease
- ejection fraction
- study protocol
- newly diagnosed
- placebo controlled
- chronic kidney disease
- phase iii
- clinical trial
- phase ii
- peritoneal dialysis
- type diabetes
- prognostic factors
- cardiovascular disease
- left ventricular
- endothelial cells
- heart failure
- squamous cell carcinoma
- patient reported outcomes
- double blind
- radiation therapy